Tuesday, December 9, 2025, 7:00 PM – 8:30 PM CT (8:00 PM – 9:30 PM ET) | San Antonio, Texas

Cases from the Community: Investigators Discuss the Role of Antibody-Drug Conjugates in the Management of Triple-Negative and HR-Positive Metastatic Breast Cancer

Part 1 of a 3-Part CME Satellite Symposium Series

Register for in-person Register for webcast

 

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 8:30 PM — Educational Meeting

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom H-L (Third Floor)

No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Javier Cortés, MD, PhD
Head, IBCC International Breast Cancer Center
Barcelona, Spain

Rita Nanda, MD
Director, Breast Oncology
Associate Professor of Medicine
Section of Hematology/Oncology
The University of Chicago
Chicago, Illinois

Professor Peter Schmid, FRCP, MD, PhD
Lead, Centre of Experimental Cancer Medicine
Barts Cancer Institute
London, United Kingdom

Priyanka Sharma, MD
Frank B Tyler Professor in Cancer Research
Division of Medical Oncology, Department of Internal Medicine
Co-Program Leader
Drug Discovery, Delivery and Experimental Therapeutics Program
The University of Kansas Cancer Center
Westwood, Kansas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida



This symposium is sponsored by Research To Practice and supported by grants from Gilead Sciences Inc and Helsinn Therapeutics (US) Inc. This is not an official program of the San Antonio Breast Cancer Symposium® (SABCS®️).
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 8:30 PM — Educational Meeting

MODULE 1: Previously Untreated Metastatic Triple-Negative Breast Cancer (mTNBC) — Prof Schmid

  • Long-term findings with and current clinical role of pembrolizumab/chemotherapy for previously untreated PD-L1-positive mTNBC
  • Scientific rationale for combining TROP2-directed antibody-drug conjugates (ADCs) with immune checkpoint inhibitors for previously untreated mTNBC
  • Key efficacy and safety data from the Phase III ASCENT-04/KEYNOTE-D19 trial evaluating sacituzumab govitecan in combination with pembrolizumab as first-line therapy for PD-L1-positive mTNBC
  • Recently presented findings from the Phase III ASCENT-03 study of sacituzumab govitecan monotherapy for patients with previously untreated advanced TNBC who are unable to receive PD-1/PD-L1 inhibitors
  • Recently presented data from the Phase III TROPION-Breast02 study of first-line datopotamab deruxtecan (Dato-DXd) versus chemotherapy for patients with advanced TNBC for whom immunotherapy was not an option

MODULE 2: Integrating ADCs into the Management of Endocrine-Resistant Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) — Dr Sharma

  • Long-term efficacy and safety findings from the Phase III TROPiCS-02 trial of sacituzumab govitecan for previously treated HR-positive, HER2-negative mBC
  • Optimal integration of sacituzumab govitecan into management algorithms for HR-positive, HER2-negative disease
  • Emerging negative outcomes from the Phase III ASCENT-07 study of sacituzumab govitecan versus chemotherapy as the first treatment after endocrine therapy for patients with HR-positive, HER2-negative mBC
  • Available efficacy and safety findings from the Phase III TROPION-Breast01 study of Dato-DXd versus investigator’s choice of chemotherapy for pretreated HR-positive, HER2-negative mBC
  • FDA approval of Dato-DXd for patients with HR-positive, HER2-negative mBC who have previously received endocrine-based therapy and chemotherapy; current clinical role
  • Available data from the DESTINY-Breast04 and DESTINY-Breast06 studies evaluating trastuzumab deruxtecan (T-DXd) versus chemotherapy for patients with previously treated HER2-low and HER2-ultralow advanced breast cancer
  • FDA approval of T-DXd for advanced HR-positive, HER2-low and HER2-ultralow breast cancer progressing after ≥1 endocrine treatment in the metastatic setting; optimal incorporation into treatment

MODULE 3: Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) mTNBC — Dr Nanda

  • Clinical and biological factors influencing the choice of treatment for patients with mTNBC progressing on first-line therapy
  • Key efficacy and safety findings from the Phase III ASCENT trial comparing sacituzumab govitecan to physician’s choice of chemotherapy for previously treated mTNBC
  • Optimal integration of sacituzumab govitecan into current mTNBC management algorithms
  • Updated data with T-DXd in the subset of patients with previously treated HR-negative, HER2-low advanced breast cancer in the Phase III DESTINY-Breast04 study; current role with regard to other available treatment options
  • Clinical trial findings with and ongoing investigation of other ADCs (eg, Dato-DXd, sacituzumab tirumotecan) for patients with R/R mTNBC

MODULE 4: Tolerability and Other Practical Considerations with ADCs and Other Cytotoxic Agents for mBC — Dr Cortés

  • Spectrum, incidence and severity of common and unique adverse events (AEs) with different ADCs employed in the management of mBC
  • Optimal approach to antiemetic prophylaxis for patients receiving ADCs and other emetogenic regimens; relative efficacy, tolerability and ease of administration of available antiemetic strategies
  • Effectiveness of netupitant/palonosetron and fosnetupitant/palonosetron in preventing acute and delayed nausea and vomiting associated with emetogenic chemotherapy regimens; role, if any, in antiemetic prophylaxis for patients receiving ADCs
  • Monitoring and management of other acute “chemotherapy-like” AEs seen with ADCs, such as cytopenias, diarrhea and fatigue
  • Recommended algorithms for mitigating more serious (eg, interstitial lung disease, left ventricular dysfunction) or unique (eg, oral mucositis/stomatitis, ocular AEs) toxicities documented with one or more ADCs

Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Review published research data supporting the use of antibody-drug conjugate (ADC) therapy alone and in combination with anti-PD-1/PD-L1 antibodies for patients with newly diagnosed triple-negative metastatic breast cancer (mBC), and use this information to make appropriate treatment recommendations.
  • Evaluate published clinical research findings with TROP2-directed ADCs for relapsed/refractory hormone receptor (HR)-positive and triple-negative mBC, and optimally incorporate these agents into the care of eligible patients.
  • Assess the biological rationale for the evaluation of HER2-directed ADCs for HER2-low and HER2-ultralow mBC, and identify patients for whom treatment with this approach would be appropriate.
  • Discern the side effects and toxicities associated with FDA-approved ADCs employed in the care of patients with mBC, and identify strategies to manage and mitigate these complications.
  • Recall ongoing trials evaluating the potential role of novel ADC-based strategies for triple-negative and HR-positive mBC, and as appropriate, counsel patients regarding enrollment.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Cortés — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, AvenCell Europe GmbH, Bioasis Technologies Inc, Biocon, BioInvent, BioNTech SE, Bliss Biopharmaceutical (Hangzhou) Co Ltd, Boehringer Ingelheim Pharmaceuticals Inc, BridgeBio, Circle Pharma, Daiichi Sankyo Inc, Delcath Systems Inc, Ellipses Pharma, ExpreS2ion Biotechnologies, Gilead Sciences Inc, Hexagon Bio, HiberCell, Jazz Pharmaceuticals Inc, Leuko-Labs, Lilly, Menarini Group, MSD, pharmaand GmbH, Reveal Genomics, Roche Laboratories Inc, Scorpion Therapeutics, Seagen Inc, Zymeworks Inc; Contracted Research Funding to Institution: AstraZeneca Pharmaceuticals LP, Baxalta GMBH/Servier Affaires, Bayer HealthCare Pharmaceuticals, Eisai Inc, F Hoffmann-La Roche Ltd, Guardant Health, IQVIA, MSD, Pfizer Inc, PIQUR Therapeutics AG, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Patents: US 2019/0338368 A1, WO 2014/199294 A; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Gilead Sciences Inc, Lilly, MSD, Novartis, Pfizer Inc, Roche Laboratories Inc, Stemline Therapeutics Inc, Zuellig Pharma; Stock OPTIONS — Private Companies: MAJ3 Capital SL; Travel, Accommodation, Expenses: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Gilead Sciences Inc, MSD, Novartis, Pfizer Inc, Roche Laboratories Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: Leuko-Labs (stock options, relative), Queen Mary University of London. Dr Nanda — Advisory Committees: Arvinas, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, GE Healthcare, Gilead Sciences Inc, Guardant Health, Lilly, Mabwell Therapeutics Inc, Merck, Moderna, Novartis, Pfizer Inc, Stemline Therapeutics Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Relay Therapeutics, Sun Pharma Advanced Research Company, Taiho Oncology Inc. Prof Schmid — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Medivation Inc, a Pfizer Company, Merck, Novartis, OncoGenex Pharmaceuticals Inc, Roche Laboratories Inc. Dr Sharma — Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Menarini Group, Merck, Novartis, Pfizer Inc, Stemline Therapeutics Inc; Contracted Research: Bristol Myers Squibb, Gilead Sciences Inc, Novartis; Data and Safety Monitoring Boards/Committees: Jazz Pharmaceuticals Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Gilead Sciences Inc and Helsinn Therapeutics (US) Inc.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom H-L (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2025 San Antonio Breast Cancer Symposium is taking place.

 
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

NOTICE
No fee is charged for this event. Please note that registration for this event is independent of registration for the San Antonio Breast Cancer Symposium.

IN-PERSON Registration
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 6:30 PM CT on Tuesday, December 9th. If you are interested in attending, please visit our registration desk outside the Grand Ballroom H-L (third floor) of the San Antonio Marriott Rivercenter hotel (101 Bowie St), within walking distance of the Henry B González Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.

NOTICE:
Registration for this event is independent of registration for SABCS.
WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.